News Releases

December 19, 2024	LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance
December 12, 2024	LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China
November 7, 2024	LakeShore Biopharma Initiates Biologics License Application of PIKA Rabies Vaccine to the Drug Regulatory Authority of Pakistan
October 29, 2024	LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
October 25, 2024	LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine
October 8, 2024	LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance
September 27, 2024	LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation
September 10, 2024	Lakeshore Biopharma to Hold an Extraordinary General Meeting of Shareholders on September 27, 2024
September 4, 2024	LakeShore Biopharma Announces Leadership Transitions
August 15, 2024	LakeShore Biopharma Announces Financial Results for Fiscal Year 2024

Print Page

Email Alerts

RSS Feeds

Contact IR

Site Map Terms of Use Privacy

Contact Info

LakeShore Biopharma, Ltd.

11 Firstfield Road Suite A
Gaithersburg, Maryland 20878 USA

Tel: +86 (10) 61253627

ir@lakeshorebio.com